Thunder Biotech

Executive Summary

Thunder Biotech is a private biotechnology company pioneering a novel class of immunotherapies based on engineered macrophages. Its proprietary MOTO-CAR platform re-engineers macrophages to recognize and attack solid tumors, addressing a critical unmet need in oncology where traditional CAR-T and checkpoint inhibitors have shown limited efficacy. Founded in 2020 and headquartered in Houston, Texas, the company aims to re-educate the patient's immune system for a more durable and humane treatment response. While still in early stages, Thunder Biotech's approach could offer a transformative option for patients with hard-to-treat solid tumors, leveraging the innate tumor-homing properties of macrophages. The company is actively advancing its pipeline toward the clinic, with a focus on demonstrating preclinical proof-of-concept and safety.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead MOTO-CAR Candidate40% success
• Q3 2026Preclinical Data Presentation at Major Oncology Conference70% success
• Q2 2026Series A Financing Round60% success